Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and pharmacokinetics of QTORIN rapamycin 3.9% anhydrous gel, called PTX-022, in adults with Pachyonychia Congenita PC who have specific keratin gene mutations and who previously participated in the PALV-05 VAPAUS trial. This open-label treatment study is conducted at multiple centers to better understand long-term exposure effects of the gel in this patient group. Participants receive the study drug PTX-022 applied as a gel, with the research focusing on monitoring safety and how the drug moves through and is processed by the body over time. The study does not have a placebo group or masking, and treatment details are based on prior enrollment and dosing established in earlier trials. Participants are monitored for treatment-emergent adverse events over six months, with pharmacokinetic measurements taken before dosing and at 12 and 24 hours after application. The trial assesses drug safety and how the body absorbs and metabolizes the gel during this period, helping researchers understand long-term use implications.
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
The trial investigates the use of YCANTH VP-102TO-208 for treating common warts in children and adults aged 2 years and older. This Phase 3 study is double-blind, randomized, and vehicle-controlled, aiming to evaluate the safety and effectiveness of YCANTH compared to a placebo vehicle. Common warts caused by the human papilloma virus HPV are the focus, excluding certain wart types and locations. Participants receive topical applications of either YCANTH or a placebo vehicle every 21 days for up to four treatments during a 75-day period. The treated warts are covered with occlusive tape overnight following the application. Treatment may be delayed if temporary local skin reactions occur, and participants must attend all scheduled treatment and follow-up visits regardless of wart clearance. In Japan, participants completing this study may join a long-term follow-up study for up to 54 weeks to monitor safety and efficacy. Participants undergo wart measurements, dermatologic exams, and evaluation of treatment responses during visits. Follow-up includes in-person visits and phone calls to assess clearance and monitor adverse events. Researchers measure the proportion of participants achieving complete wart clearance at Day 84 and monitor safety through adverse event reporting and skin reaction assessments. The total participant involvement spans screening, treatment, and follow-up periods totaling several months.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.
Actively Recruiting
Researchers are evaluating ORKA-002, a drug administered by subcutaneous injection, in adult participants with moderate-to-severe Hidradenitis Suppurativa HS. This multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacokinetics of ORKA-002 compared to placebo. The study is sponsored by Oruka Therapeutics, Inc. and involves participants who have had HS symptoms for at least 6 months with lesions in multiple areas and prior inadequate response or intolerance to systemic antibiotics. Participants will be randomly assigned to receive either ORKA-002 or placebo every 4 weeks during a 12-week double-blind induction period through Week 16. After this, all participants will enter an open-label maintenance period where ORKA-002 is given every 12 weeks. The study includes four distinct periods screening, induction double-blind, maintenance open-label, and post-treatment follow-up. During the study, participants will undergo regular assessments including the Hidradenitis Suppurativa Clinical Response HiSCR75 at Week 16, symptom diaries tracking worst skin pain, and safety monitoring through vital signs, laboratory tests, and electrocardiograms. The total study participation may extend through Week 92 for ongoing safety evaluations. Participants will also be monitored for adverse events throughout the study duration.
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.
Actively Recruiting
Researchers are establishing a Research Sample Repository to collect blood samples related to histocompatibility and hematopoietic cell transplantation HCT or other cellular therapies. This repository supports research aimed at understanding molecular factors affecting transplant outcomes, studying tissue type distributions, and evaluating the success of transplantation and supportive care in marrow toxic injuries. The research includes anonymous studies and aims to facilitate broader scientific investigations in these areas. The repository accepts samples from four main groups donors of hematopoietic cells or other cellular therapies, cord blood units used in treatment, recipients of hematopoietic cell transplants or cellular therapies, and patients treated for marrow toxic injuries. Samples come from donors who have donated or plan to donate cells, cord blood units infused at treatment centers, transplant or therapy recipients, and marrow toxic injury patients receiving various treatments including supportive care or stem cell transplants. Participants contribute samples that are made available to researchers for various analyses including genomic and biomolecular studies. The primary goal is to provide blood samples for research related to histocompatibility and transplantation outcomes. Participation includes adults and children with or without decision-making capacity. The repository facilitates access to these samples for approved research, supporting studies from multiple centers and investigators over an extended period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a reformulated Levulan Kerastick solution combined with photodynamic therapy PDT to treat actinic keratosis AK on the face or bald scalp. This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study focuses on adults with 4 to 8 mild to moderate AK lesions. The study aims to measure the complete clearance rate of these lesions at 12 weeks and also assesses other outcomes like partial clearance, lesion count changes, recurrence, cosmetic results, and patient satisfaction. Participants are assigned to one of four groups based on whether they receive the active drug or a vehicle solution and on two different incubation times before blue light application. Up to two PDT sessions may be given depending on lesion clearance. The active drug is a topical solution of aminolevulinic acid hydrochloride ALA HCl 20%, compared to a vehicle solution without the active ingredient. A blue light PDT device is used during the treatment. During the study, participants will have clinic visits to assess lesion clearance and safety through evaluations of skin reactions, vital signs, and lab tests. Researchers will track outcomes at weeks 4, 8, 12, 20, and 24, including lesion clearance rates, cosmetic response, and patient satisfaction. The total study duration extends through these follow-up assessments, with safety monitoring throughout and a final evaluation at week 24.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new formulation of Levulan Kerastick combined with photodynamic therapy PDT to treat actinic keratosis AK on the upper arms. This Phase 3, randomized, multi-center, and evaluator-blind study compares this treatment to a vehicle control in adults with mild to moderate AK lesions. The goal is to see how well the treatment clears the lesions and to assess its safety. Participants will be randomly assigned to receive either the Levulan Kerastick solution or a vehicle solution applied to the skin, followed by an incubation period under occlusion and exposure to blue light using a specialized device. Up to two PDT sessions may be given depending on how well lesions clear. The study includes multiple time points for assessing lesion clearance, cosmetic outcomes, patient satisfaction, and recurrence rates. Throughout the study, participants will be monitored through visits where the skin lesions are evaluated, safety assessments are made including skin reactions and lab tests, and patient feedback is collected. The primary outcome focuses on the complete clearance rate of AK lesions at Week 12. Secondary outcomes involve lesion clearance at various weeks up to 24, cosmetic responses, and recurrence. The total study duration includes treatment and follow-up assessments extending to Week 24.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ICP-332 in adults with Prurigo Nodularis PN, a skin condition characterized by itchy nodules. This study is a Phase 2 clinical trial designed to compare different doses of ICP-332 against a placebo to better understand its potential benefits and risks for people with PN. Participants are randomly assigned to receive either ICP-332 at doses of 80 mg or 120 mg, or a placebo, with neither the participants nor the researchers knowing which treatment is given to ensure unbiased results. The study involves a 16-week treatment period to assess itch severity, followed by continued assessments up to 40 weeks to monitor skin condition improvements, quality of life, and any side effects. Blood tests will measure how the drug is processed by the body. Throughout the study, participants will be monitored regularly with evaluations of their itch intensity using a numeric scale, skin assessments by doctors, and quality of life questionnaires. Safety will be closely tracked by recording any adverse events. Participants involvement may last up to 40 weeks, including treatment and follow-up periods to gather comprehensive information about ICP-332s impact on Prurigo Nodularis.